Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27527505 | 0.98 | FPR2 (0.42) | FPR2CTSKCTSSNOD1FOLH1 | |
| SCHEMBL27754766 | 0.96 | FPR2 (0.41) | FPR2CTSKCTSSNOD1FOLH1 | |
| SCHEMBL9832042 | 0.89 | NOD1 (0.49) | CTSKCTSSNOD1HDAC2MAPK1 | |
| SCHEMBL9832048 | 0.89 | NOD1 (0.49) | CTSKCTSSNOD1HDAC2MAPK1 | |
| SCHEMBL6269749 | 0.87 | NOD1 (0.51) | NOD1FOLH1MAPK1SMN1; SMN2TGM2 | |
| SCHEMBL29153240 | 0.85 | ATM (0.39) | NOD1FOLH1ITGB3ITGAVMAPK1 | |
| SCHEMBL29153242 | 0.85 | ATM (0.39) | NOD1FOLH1ITGB3ITGAVMAPK1 | |
| SCHEMBL15045574 | 0.85 | SMN1; SMN2 (0.40) | CTSKCTSSMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL387926 | 0.84 | TGFBR1 (0.46) | FPR2CTSKCTSSNOD1FOLH1 | |
| SCHEMBL387925 | 0.84 | TGFBR1 (0.46) | FPR2CTSKCTSSNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| EP-2069364-B1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2069364-B1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20110105537-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105537-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| EP-2069364-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318981-A1 | Novel Compounds 480 | CX3CR1, CCR2, CXCR3 | FPR2 39/4885CTSK 2319/4885CTSS 2498/4885 |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | CX3CR1, CCR2, CXCR3 | FPR2 18/4885CTSK 3356/4885CTSS 3367/4885 |
| US-20110105537-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES FOR THE SELECTIVE INHIBITION OF CHEMOKINE RECEPTORS | CX3CR1, CCR2, CXCR3 | FPR2 30/4885CTSK 3006/4885CTSS 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.